RALOXIFENE HYDROCHLORIDE belongs to the class of medicines called selective estrogen receptor modulators. It is used to treat and prevent osteoporosis in post-menopausal women. This medicine reduces the risk of vertebral fractures in women with post-menopausal osteoporosis. Post-menopausal osteoporosis is a medical condition that causes thinning and weakening of the bones during/after a menopausal period.
RALOXIFENE HYDROCHLORIDE consists of Raloxifene hydrochloride, which belongs to a class of non-hormonal medications known as Selective Oestrogen Receptor Modulators (SERMs). When a woman achieves menopause, the level of the female sex hormone oestrogen decreases. This medication replicates some of the beneficial effects of oestrogen after menopause.
Take RALOXIFENE HYDROCHLORIDE as prescribed by your doctor. You are advised to take RALOXIFENE HYDROCHLORIDE for as long as your doctor has prescribed it for you based on your medical condition. Sometimes, you may experience nausea, vomiting, abdominal pain and stomach upset, increased blood pressure, hot flushes (vasodilation) and flu syndrome. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.
RALOXIFENE HYDROCHLORIDE is only for post-menopausal women and should not be taken by pregnant women or those planning to get pregnant. This medication may be harmful to your unborn child. If breastfeeding, do not take this medication because it may be excreted in the breast milk. If you are lactose intolerant, inform your doctor before taking this medication. It is recommended not to use if you are allergic to raloxifene or any of the other ingredients of this medicine if you have liver disease, severe kidney problems, active uterine cancer, or any unexplained vaginal bleeding. So, inform your doctor about your medical condition.
Postmenopausal osteoporosis
RALOXIFENE HYDROCHLORIDE consists of Raloxifene hydrochloride, which belongs to a class of non-hormonal medications known as Selective Oestrogen Receptor Modulators (SERMs). When a woman achieves menopause, the level of the female sex hormone oestrogen decreases. This medication replicates some of the beneficial effects of oestrogen after menopause. Raloxifene hydrochloride is also used to reduce the chance of developing invasive breast cancer (breast cancer that has progressed outside of the milk ducts or lobules into the surrounding breast tissue) in postmenopausal women at high risk or with osteoporosis.
Inform your doctor about any allergic or hypersensitive reactions to drugs or food before taking the RALOXIFENE HYDROCHLORIDE. Inform your doctor about your medical history and current drugs to rule out any potential side effects. RALOXIFENE HYDROCHLORIDE is only for postmenopausal women. As a result, it should not be used if you are pregnant or breastfeeding. It is not suggested for usage in children.
Drug-Drug Interactions: RALOXIFENE HYDROCHLORIDE may interact with anti-cancer drugs (e.g. bexarotene, carfilzomib, lenalidomide, pomalidomide), certain diagnostic agents (e.g. fluoroestradiol F 18), immunomodulatory class of medications (e.g. thalidomide), and antifibrinolytic medications (e.g. tranexamic acid).
Drug-Food Interactions: Avoid the consumption of alcoholic beverages.
Drug-Disease Interactions: RALOXIFENE HYDROCHLORIDE interact with various disease conditions, including liver disease (examples of liver disease include cirrhosis, mild hepatic impairment or cholestatic jaundice), Heart disorders, pulmonary disorders, kidney problems, unexplained vaginal bleeding, and active uterine cancer.
No interaction was found. However, it is advisable not to take or limit alcohol as a precautionary measure.
RALOXIFENE HYDROCHLORIDE is only recommended for post-menopausal women. It is not recommended to use in pregnancy as it may harm the fetus.
Do not take this medicine if you are breastfeeding, as it might be excreted in breast milk and may harm your child.
RALOXIFENE HYDROCHLORIDE usually does not affect your ability to drive or operate machinery.
It is not recommended for use in patients with liver disease (examples of liver disease include cirrhosis, mild hepatic impairment or cholestatic jaundice). Inform your doctor before receiving the RALOXIFENE HYDROCHLORIDE if you have had a liver impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
It is not recommended in patients with moderate or severe hepatic insufficiency. Inform your doctor before receiving the RALOXIFENE HYDROCHLORIDE if you have had a kidney impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
RALOXIFENE HYDROCHLORIDE is not recommended for children.
Postmenopausal osteoporosis: Postmenopausal osteoporosis is a medical disorder that causes bone loss and weakness during and after menopause. Estrogen insufficiency increases the risk of developing osteoporosis (weak bones). The decline in oestrogen during the menopause era (45 years of age) causes more bone resorption (osteoclasts; bone disintegration) than creation (osteoblasts; new bone development), leading to osteoporosis. Osteoporosis has no symptoms in the early stages. Yet, if sufficient care is not given, it might result in shattered bones. The bones do not pain at first, and breaks in the spine's bones may go unnoticed until they cause height reduction. Bones with osteoporosis might shatter at any time, even during normal tasks such as lifting or small activities.